Poor applicability of estimation method for adults to calculate unbound serum concentrations of valproic acid in epileptic neonates and infants

Journal of Clinical Pharmacy and Therapeutics

Volumn 34, Issue 4, 2009, Pages 415-422

  Ueshima, S ^a,b   Aiba, T ^b   Ishikawa, N ^b   Sato, T ^a   Kawasaki, H ^b   Kurosaki, Y ^b   Ohtsuka, Y ^a   Sendo, T ^a,b  

^a OKAYAMA UNIVERSITY HOSPITAL   (Japan)

^b OKAYAMA UNIVERSITY   (Japan)

Author keywords

Epilepsy; Neonates; Therapeutic drug monitoring; Unbound concentration; Valproic acid

Indexed keywords

ALBUMIN; CLONAZEPAM; PHENOBARBITAL; PHENYTOIN; PRIMIDONE; VALPROIC ACID; ZONISAMIDE;

ADOLESCENT; ADULT; ALBUMIN BLOOD LEVEL; ANTICONVULSANT THERAPY; ARTICLE; BENIGN CHILDHOOD EPILEPSY; CHILD; CLINICAL EXAMINATION; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG MONITORING; EPILEPSY; FEMALE; FOCAL EPILEPSY; GROUPS BY AGE; HUMAN; INFANT; INFANT DISEASE; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MONOTHERAPY; MORNING DOSAGE; NEWBORN; NEWBORN DISEASE; PRESCHOOL CHILD; REFERENCE VALUE; SCHOOL CHILD;

ADOLESCENT; ADULT; AGE FACTORS; ANTICONVULSANTS; CHILD; CHILD, PRESCHOOL; DRUG MONITORING; EPILEPSY; FEMALE; HUMANS; INFANT; INFANT, NEWBORN; MALE; PROTEIN BINDING; REFERENCE VALUES; RETROSPECTIVE STUDIES; SERUM ALBUMIN; VALPROIC ACID; YOUNG ADULT;

EID: 67651250901     PISSN: 02694727     EISSN: 13652710     Source Type: Journal    
DOI: 10.1111/j.1365-2710.2009.01022.x     Document Type: Article

References (35)

1. Prats JM, Garaizar C, Rua MJ, Garcia-Nieto ML, Madoz P (1991) Infantile spasms treated with high doses of sodium valproate: initial response and follow-up. Developmental Medicine and Child Neurology, 33, 617 625.
2. Ohtsuka Y, Amano R, Mizukawa M, Oka E, Ohtahara S (1992) Treatment of intractable childhood epilepsy with high-dose valproate. Epilepsia, 33, 158 164.
3. Davis R, Peters DH, McTavish D (1994) Valproic acid. A reappraisal of its pharmacological properties and clinical efficacy in epilepsy. Drugs, 47, 332 372.
4. Graves NM, Garnett WR (1999) Epilepsy. In : Dipiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey LM, eds. Pharmacotherapy: a pathophysiological approach (4/e). Norwalk : Appleton & Lange, 952 975.
5. McEvoy GK (2002) AHFS drug information. Bethesda : American Society of Health-System Pharmacists.
6. Wilder BJ, Karas BJ, Penry JK, Asconape J (1983) Gastrointestinal tolerance of divalproex sodium. Neurology, 33, 808 811.
7. Keown P, McAllister-Williams H, Young A (2006) A case of pancytopenia. Journal of Psychopharmacology, 20, 690 692.
8. König SA, Schenk M, Sick C et al. (1999) Fatal liver failure associated with valproate therapy in a patient with Friedreich's disease: review of valproate hepatotoxicity in adults. Epilepsia, 40, 1036 1040.
9. Acharya S, Bussel JB (2000) Hematologic toxicity of sodium valproate. Journal of Pediatric Hematology/Oncology, 22, 62 65.
10. Yamanouchi H, Ota T, Imataka G, Nakagawa E, Eguchi M (2003) Reversible altered consciousness with brain atrophy caused by valproic acid. Pediatric Neurology, 28, 382 384.
11. Cuturic M, Abramson RK (2005) Acute hyperammonemic coma with chronic valproic acid therapy. The Annals of Pharmacotherapy, 39, 2119 2123.
12. Rath A, Naryanan TJ, Chowdhary GV, Murthy JM (2005) Valproate-induced hyperammonemic encephalopathy with normal liver function. Neurology India, 53, 226 228.
13. Record CO, Buxton B, Chase RA, Curzon G, Murray-Lyon IM, Williams R (1976) Plasma and brain amino acids in fulminant hepatic failure and their relationship to hepatic encephalopathy. European Journal of Clinical Investigation, 6, 387 394.
14. McConnell JR, Antonson DL, Ong CS et al. (1995) Proton spectroscopy of brain glutamine in acute liver failure. Hepatology, 22, 69 74.
15. Pichili VB, Rao KV, Jayakumar AR, Norenberg MD (2007) Inhibition of glutamine transport into mitochondria protects astrocytes from ammonia toxicity. Glia, 55, 801 809.
16. Raskind JY, El-Chaar GM (2000) The role of carnitine supplementation during valproic acid therapy. The Annals of Pharmacotherapy, 34, 630 638.
17. Segura-Bruna N, Rodriguez-Campello A, Puente V, Roquer J (2006) Valproate-induced hyperammonemic encephalopathy. Acta Neurologica Scandinavica, 114, 1 7.
18. Limketkai BN, Zucker SD (2008) Hyperammonemic encephalopathy caused by carnitine deficiency. Journal of General Internal Medicine, 23, 210 213.
19. Matsuda I, Ohtani Y, Ninomiya N (1986) Renal handling of carnitine in children with carnitine deficiency and hyperammonemia associated with valproate therapy. The Journal of Pediatrics, 109, 131 134.
20. Eyer F, Felgenhauer N, Gempel K, Steimer W, Gerbitz KD, Zilker T (2005) Acute valproate poisoning: pharmacokinetics, alteration in fatty acid metabolism, and changes during therapy. Journal of Clinical Psychopharmacology, 25, 376 380.
21. Milsap RL, Szefler SJ (1986) Special pharmacokinetic considerations in children. In : Evans WE, Schentag JJ, Jusko WJ, eds. Applied pharmacokinetics. Spokane : Applied Therapeutics Inc, 294 330.
22. Rodier PM (1995) Developing brain as a target of toxicity. Environmental Health Perspectives, 103, S73 S76.
23. Mayerhoff DI, Nurenberg J, Shah S, Schleifer SJ (2005) Neurotoxicity associated with free valproic acid. The American Journal of Psychiatry, 162, 810.
24. Dasgupta A (2007) Usefulness of monitoring free (unbound) concentrations of therapeutic drugs in patient management. Clinica Chimica Acta, 377, 1 13.
25. Sundqvist A, Tomson T, Lundkvist B (1997) Pharmacokinetics of valproic acid in patients with juvenile myoclonic epilepsy on monotherapy. Therapeutic Drug Monitoring, 19, 153 159.
26. Kodama Y, Kodama H, Kuranari M, Tsutsumi K, Ono S, Fujimura A (1999) No effect of gender or age on binding characteristics of valproic acid to serum proteins in pediatric patients with epilepsy. Journal of Clinical Pharmacology, 39, 1070 1076.
27. Ueshima S, Aiba T, Makita T et al. (2008) Characterization of nonlinear relationship between total and unbound serum concentrations of valproic acid in epileptic children. Journal of Clinical Pharmacy and Therapeutics, 33, 31 38.
28. Scheyer RD, Cramer JA, Toftness BR, Hochholzer JM, Mattson RH (1990) In vivo determination of valproate binding constants during sole and multi-drug therapy. Therapeutic Drug Monitoring, 12, 117 123.
29. Yu HY (1984) Clinical implications of serum protein binding in epileptic children during sodium valproate maintenance therapy. Therapeutic Drug Monitoring, 6, 414 423.
30. Herngren L, Lundberg B, Nergardh A (1991) Pharmacokinetics of total and free valproic acid during monotherapy in infants. Journal of Neurology, 238, 315 319.
31. Alcorn J, McNamara PJ (2002) Ontogeny of hepatic and renal systemic clearance pathways in infants: Part I. Clinical Pharmacokinetics, 41, 959 998. (Pubitemid 35168438)
32. McNamara PJ, Alcorn J (2002) Protein binding predictions in infants. AAPS PharmSci, 4, E4.
33. Fleming J, Chetty M (2005) Psychotropic drug interactions with valproate. Clinical Neuropharmacology, 28, 96 101.
34. Gerstner T, Buesing D, Longin E et al. (2006) Valproic acid induced encephalopathy - 19 new cases in Germany from 1994 to 2003 - a side effect associated to VPA-therapy not only in young children. Seizure, 15, 443 448.
35. Verrotti A, Trotta D, Morgese G, Chiarelli F (2002) Valproate-induced hyperammonemic encephalopathy. Metabolic Brain Disease, 17, 367 373.